176
Participants
Start Date
January 20, 2016
Primary Completion Date
July 16, 2021
Study Completion Date
July 16, 2021
Tofersen
Administered as specified in the treatment arm.
Placebo
Administered as specified in the treatment arm.
Westmead Hospital, Westmead
Bispebjerg Hospital, Copenhagen
UZ Leuven, Leuven
Columbia University Medical Center, New York
"ALS Center - Dept. of Neuroscience Rita Levi Montalcini, University of Turin", Torino
University of Pennsylvania, Philadelphia
Johns Hopkins University, Baltimore
Emory University Hospital, Atlanta
Mayo Clinic in Florida, Jacksonville
Bioclinica Research, Orlando
University of Miami School of Medicine, Miami
New Orleans Center for Clinical Research/Volunteer Research Group, an AMR Company, Knoxville
The Cleveland Clinic Foundation, Cleveland
Henry Ford Hospital, Detroit
Research Site, Yangsan
Mayo Clinic - Rochester, Rochester
Northwestern University Feinberg School of Medicine, Chicago
Washington University School of Medicine, St Louis
Neurology Associates, P.C., Lincoln
Hopital Pitie Salpetriere, Paris
Methodist Neurological Institute, Houston
Barrow Neurological Institute, Phoenix
University of Ulm, Ulm
University of California San Diego Medical Center, La Jolla
California Pacific Medical Center, San Francisco
Providence ALS Center, Portland
Massachusetts General Hospital, Boston
University of Calgary - Health Sciences Centre, Calgary
Research Site, Edmonton
Sunnybrook Health Sciences Centre, Toronto
Montreal Neurological Institute, Montreal
The University of Tokyo Hospital, Bunkyō City
Research Site, Fukuoka
Research Site, Kagoshima
Research Site, Shinjuku-ku
Research Site, Suita-Shi
Research Site, Warsaw
Research Site, Seoul
Research Site, London
Research Site, Sheffield
Lead Sponsor
Collaborators (1)
Ionis Pharmaceuticals, Inc.
INDUSTRY
Biogen
INDUSTRY